Iconic Australian Company Adopts New Look as a Global Organisation

Iconic Australian Company Adopts New Look as a Global Organisation

Melbourne, Australia — 23/08/2006

CSL Limited, Australia’s leading biopharmaceutical company, today announced an updated look with a new logo to bring together its Australian and offshore group of companies together as a single global entity.

The changes are designed to present a consistent and compelling view of CSL as an Australian company, operating in new and established markets around the world.

‘We are using CSL as the common foundation which means our international ZLB Behring plasma therapeutics business will be renamed CSL Behring. In Australia, we’ve replaced ‘CSL Pharmaceuticals’ with ‘CSL Biotherapies’, which will support the manufacture, sale and distribution of influenza vaccine worldwide. CSL Bioplasma, our Australian plasma  therapeutics business will retain its name reflecting its unique position as Australia’s national fractionator’ CEO Dr Brian McNamee said today.

‘This year CSL will be providing flu vaccine from Australia to international markets, launching its Australian-invented cervical cancer vaccine and further investing in solutions for  pandemic flu, it’s time to bring a new brand into the 21st century which reflects what we actually do’ Dr McNamee said.

CSL was formerly known as the Commonwealth Serum Laboratories, a Federal Government statutory authority, and was privatised in 1994 at an estimated value of $300 million. It is now a global, specialty biopharmaceutical company providing a range of products to treat and prevent serious medical conditions with a market capitalisation of approximately $9 billion. This year almost $200 million will be invested in medical research and development.

Headquartered in Melbourne Australia, the CSL Group includes CSL Bioplasma, CSL Biotherapies and CSL Behring incorporating ZLB Plasma Services. With major facilities in Australia, Germany, Switzerland and US, CSL has approximately 7500 employees working in 26 countries.

The business units within CSL will be renamed as follows:

CSL Behring-

previously known as ZLB Behring, headquartered in King of Prussia, outside Philadelphia USA, and a global leader in plasma therapeutics. ZLB Plasma Services will retain its current name to preserve its strong relationship with donors.

CSL Bioplasma-the national plasma fractionator of Australia, New Zealand, Hong Kong, Singapore and Malaysia will retain the name CSL Bioplasma.

CSL Biotherapies -a new business entity established to replace the local operation of CSL Pharmaceuticals and support CSL’s influenza vaccine business globally.

The CSL Limited Logo is to be replaced by the red logo as seen above, to be used by all Australian and offshore business units.

For further information please contact:

Media Contacts
Dr Rachel David
Director of Public Affairs
Phone: 0401 775 779

Investor Contacts
Mr Mark Dehring
Director of Investor Relations
Phone: 61 3 9389 2818
© 2017 CSL Limited